Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the ...

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque ... psoriasis the unique combination of a favorable safety profile and complete skin ...